H2N2V1, PascalFrancis, Curation, bibRecord, 000019

Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate

Identifieur interne : 000019 ( PascalFrancis/Curation ); précédent : 000018; suivant : 000020

Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate

Auteurs : H. Chen [États-Unis] ; Y. Matsuoka [États-Unis] ; David Swayne [États-Unis] ; Q. Chen [États-Unis] ; N. J. Cox [États-Unis] ; B. R. Murphy [États-Unis] ; K. Subbarao [États-Unis]

Source :

Vaccine [ 0264-410X ] ; 2003.

RBID : Pascal:04-0415778

Descripteurs français

Pascal (Inist)
- Virus grippal A, Influenzavirus, Souche atténuée, Vaccin, Immunogénicité, Immunoprotection, Souris, Grippe A, Réassortiment génétique.
Wicri :
- topic : Vaccin.

English descriptors

KwdEn :
- Attenuated strain, Genetic reassortment, Immunogenicity, Immunoprotection, Influenza A, Influenza A virus, Influenzavirus, Mouse, Vaccine.

Abstract

H9N2 subtype influenza A viruses have been identified in avian species worldwide and were isolated from humans in 1999, raising concerns about their pandemic potential and prompting the development of candidate vaccines to protect humans against this subtype of influenza A virus. Reassortant H1N1 and H3N2 human influenza A viruses with the internal genes of the influenza A/Ann Arbor/6/60 (H2N2) (AA) cold-adapted (ca) virus have proven to be attenuated and safe as live virus vaccines in humans. Using classical genetic reassortment, we generated a reassortant virus (G9/AA ca) that contains the hemagglutinin and neuraminidase genes from influenza A/chicken/Hong Kong/G9/97 (H9N2) (G9) and six internal gene segments from the AA ca virus. When administered intranasally, the reassortant virus was immunogenic and protected mice from subsequent challenge with wild-type H9N2 viruses, although it was restricted in replication in the respiratory tract of mice. The G9/AA ca virus bears properties that are desirable in a vaccine for humans and is available for clinical evaluation and use, should the need arise.

A01	`01`	`1`		`@0 0264-410X`
A02	`01`			`@0 VACCDE`
A03		`1`		`@0 Vaccine`
A05				`@2 21`
A06				`@2 27-30`
A08	`01`	`1`	`ENG`	`@1 Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate`
A11	`01`	`1`		`@1 CHEN (H.)`
A11	`02`	`1`		`@1 MATSUOKA (Y.)`
A11	`03`	`1`		`@1 SWAYNE (David)`
A11	`04`	`1`		`@1 CHEN (Q.)`
A11	`05`	`1`		`@1 COX (N. J.)`
A11	`06`	`1`		`@1 MURPHY (B. R.)`
A11	`07`	`1`		`@1 SUBBARAO (K.)`
A14	`01`			`@1 Influenza Branch, CDC @2 Atlanta, GA @3 USA @Z 1 aut. @Z 2 aut. @Z 4 aut. @Z 5 aut. @Z 7 aut.`
A14	`02`			`@1 Southeast Poultry Research Laboratory, ARS, USDA @2 Athens, GA @3 USA @Z 3 aut.`
A14	`03`			`@1 Laboratory of Infectious Diseases, NIAID, NIH, Building 50, Room 6132, MSC 8007, 50 South Drive @2 Bethesda, MD 20892-8007 @3 USA @Z 6 aut. @Z 7 aut.`
A20				`@1 4430-4436`
A21				`@1 2003`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20289 @5 354000114965520420`
A44				`@0 0000 @1 © 2004 INIST-CNRS. All rights reserved.`
A45				`@0 29 ref.`
A47	`01`	`1`		`@0 04-0415778`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Vaccine`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 H9N2 subtype influenza A viruses have been identified in avian species worldwide and were isolated from humans in 1999, raising concerns about their pandemic potential and prompting the development of candidate vaccines to protect humans against this subtype of influenza A virus. Reassortant H1N1 and H3N2 human influenza A viruses with the internal genes of the influenza A/Ann Arbor/6/60 (H2N2) (AA) cold-adapted (ca) virus have proven to be attenuated and safe as live virus vaccines in humans. Using classical genetic reassortment, we generated a reassortant virus (G9/AA ca) that contains the hemagglutinin and neuraminidase genes from influenza A/chicken/Hong Kong/G9/97 (H9N2) (G9) and six internal gene segments from the AA ca virus. When administered intranasally, the reassortant virus was immunogenic and protected mice from subsequent challenge with wild-type H9N2 viruses, although it was restricted in replication in the respiratory tract of mice. The G9/AA ca virus bears properties that are desirable in a vaccine for humans and is available for clinical evaluation and use, should the need arise.
C02	`01`	`X`		`@0 002A05C07`
C03	`01`	`X`	`FRE`	`@0 Virus grippal A @2 NW @5 01`
C03	`01`	`X`	`ENG`	`@0 Influenza A virus @2 NW @5 01`
C03	`01`	`X`	`SPA`	`@0 Influenza A virus @2 NW @5 01`
C03	`02`	`X`	`FRE`	`@0 Influenzavirus @2 NW @5 02`
C03	`02`	`X`	`ENG`	`@0 Influenzavirus @2 NW @5 02`
C03	`02`	`X`	`SPA`	`@0 Influenzavirus @2 NW @5 02`
C03	`03`	`X`	`FRE`	`@0 Souche atténuée @5 03`
C03	`03`	`X`	`ENG`	`@0 Attenuated strain @5 03`
C03	`03`	`X`	`SPA`	`@0 Cepa atenuada @5 03`
C03	`04`	`X`	`FRE`	`@0 Vaccin @5 05`
C03	`04`	`X`	`ENG`	`@0 Vaccine @5 05`
C03	`04`	`X`	`SPA`	`@0 Vacuna @5 05`
C03	`05`	`X`	`FRE`	`@0 Immunogénicité @5 06`
C03	`05`	`X`	`ENG`	`@0 Immunogenicity @5 06`
C03	`05`	`X`	`SPA`	`@0 Inmunogenicidad @5 06`
C03	`06`	`X`	`FRE`	`@0 Immunoprotection @5 07`
C03	`06`	`X`	`ENG`	`@0 Immunoprotection @5 07`
C03	`06`	`X`	`SPA`	`@0 Inmunoprotección @5 07`
C03	`07`	`X`	`FRE`	`@0 Souris @5 08`
C03	`07`	`X`	`ENG`	`@0 Mouse @5 08`
C03	`07`	`X`	`SPA`	`@0 Ratón @5 08`
C03	`08`	`X`	`FRE`	`@0 Grippe A @5 14`
C03	`08`	`X`	`ENG`	`@0 Influenza A @5 14`
C03	`08`	`X`	`SPA`	`@0 Gripe A @5 14`
C03	`09`	`X`	`FRE`	`@0 Réassortiment génétique @4 CD @5 96`
C03	`09`	`X`	`ENG`	`@0 Genetic reassortment @4 CD @5 96`
C07	`01`	`X`	`FRE`	`@0 Influenzavirus A @2 NW`
C07	`01`	`X`	`ENG`	`@0 Influenzavirus A @2 NW`
C07	`01`	`X`	`SPA`	`@0 Influenzavirus A @2 NW`
C07	`02`	`X`	`FRE`	`@0 Orthomyxoviridae @2 NW`
C07	`02`	`X`	`ENG`	`@0 Orthomyxoviridae @2 NW`
C07	`02`	`X`	`SPA`	`@0 Orthomyxoviridae @2 NW`
C07	`03`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`03`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`03`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`04`	`X`	`FRE`	`@0 Rodentia @2 NS`
C07	`04`	`X`	`ENG`	`@0 Rodentia @2 NS`
C07	`04`	`X`	`SPA`	`@0 Rodentia @2 NS`
C07	`05`	`X`	`FRE`	`@0 Mammalia @2 NS`
C07	`05`	`X`	`ENG`	`@0 Mammalia @2 NS`
C07	`05`	`X`	`SPA`	`@0 Mammalia @2 NS`
C07	`06`	`X`	`FRE`	`@0 Vertebrata @2 NS`
C07	`06`	`X`	`ENG`	`@0 Vertebrata @2 NS`
C07	`06`	`X`	`SPA`	`@0 Vertebrata @2 NS`
C07	`07`	`X`	`FRE`	`@0 Virose @2 NM`
C07	`07`	`X`	`ENG`	`@0 Viral disease @2 NM`
C07	`07`	`X`	`SPA`	`@0 Virosis @2 NM`
C07	`08`	`X`	`FRE`	`@0 Infection @2 NM`
C07	`08`	`X`	`ENG`	`@0 Infection @2 NM`
C07	`08`	`X`	`SPA`	`@0 Infección @2 NM`
N21				`@1 236`
N44	`01`			`@1 PSI`
N82				`@1 PSI`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000055

Links to Exploration step

Pascal:04-0415778

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate</title>
<author><name sortKey="Chen, H" sort="Chen, H" uniqKey="Chen H" first="H." last="Chen">H. Chen</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Influenza Branch, CDC</s1>
<s2>Atlanta, GA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Matsuoka, Y" sort="Matsuoka, Y" uniqKey="Matsuoka Y" first="Y." last="Matsuoka">Y. Matsuoka</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Influenza Branch, CDC</s1>
<s2>Atlanta, GA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Swayne, David" sort="Swayne, David" uniqKey="Swayne D" first="David" last="Swayne">David Swayne</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Southeast Poultry Research Laboratory, ARS, USDA</s1>
<s2>Athens, GA</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Chen, Q" sort="Chen, Q" uniqKey="Chen Q" first="Q." last="Chen">Q. Chen</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Influenza Branch, CDC</s1>
<s2>Atlanta, GA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Cox, N J" sort="Cox, N J" uniqKey="Cox N" first="N. J." last="Cox">N. J. Cox</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Influenza Branch, CDC</s1>
<s2>Atlanta, GA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Murphy, B R" sort="Murphy, B R" uniqKey="Murphy B" first="B. R." last="Murphy">B. R. Murphy</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Laboratory of Infectious Diseases, NIAID, NIH, Building 50, Room 6132, MSC 8007, 50 South Drive</s1>
<s2>Bethesda, MD 20892-8007</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Subbarao, K" sort="Subbarao, K" uniqKey="Subbarao K" first="K." last="Subbarao">K. Subbarao</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Influenza Branch, CDC</s1>
<s2>Atlanta, GA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Laboratory of Infectious Diseases, NIAID, NIH, Building 50, Room 6132, MSC 8007, 50 South Drive</s1>
<s2>Bethesda, MD 20892-8007</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0415778</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 04-0415778 INIST</idno>
<idno type="RBID">Pascal:04-0415778</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000055</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000019</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate</title>
<author><name sortKey="Chen, H" sort="Chen, H" uniqKey="Chen H" first="H." last="Chen">H. Chen</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Influenza Branch, CDC</s1>
<s2>Atlanta, GA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Matsuoka, Y" sort="Matsuoka, Y" uniqKey="Matsuoka Y" first="Y." last="Matsuoka">Y. Matsuoka</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Influenza Branch, CDC</s1>
<s2>Atlanta, GA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Swayne, David" sort="Swayne, David" uniqKey="Swayne D" first="David" last="Swayne">David Swayne</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Southeast Poultry Research Laboratory, ARS, USDA</s1>
<s2>Athens, GA</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Chen, Q" sort="Chen, Q" uniqKey="Chen Q" first="Q." last="Chen">Q. Chen</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Influenza Branch, CDC</s1>
<s2>Atlanta, GA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Cox, N J" sort="Cox, N J" uniqKey="Cox N" first="N. J." last="Cox">N. J. Cox</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Influenza Branch, CDC</s1>
<s2>Atlanta, GA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Murphy, B R" sort="Murphy, B R" uniqKey="Murphy B" first="B. R." last="Murphy">B. R. Murphy</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Laboratory of Infectious Diseases, NIAID, NIH, Building 50, Room 6132, MSC 8007, 50 South Drive</s1>
<s2>Bethesda, MD 20892-8007</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Subbarao, K" sort="Subbarao, K" uniqKey="Subbarao K" first="K." last="Subbarao">K. Subbarao</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Influenza Branch, CDC</s1>
<s2>Atlanta, GA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Laboratory of Infectious Diseases, NIAID, NIH, Building 50, Room 6132, MSC 8007, 50 South Drive</s1>
<s2>Bethesda, MD 20892-8007</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Attenuated strain</term>
<term>Genetic reassortment</term>
<term>Immunogenicity</term>
<term>Immunoprotection</term>
<term>Influenza A</term>
<term>Influenza A virus</term>
<term>Influenzavirus</term>
<term>Mouse</term>
<term>Vaccine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Virus grippal A</term>
<term>Influenzavirus</term>
<term>Souche atténuée</term>
<term>Vaccin</term>
<term>Immunogénicité</term>
<term>Immunoprotection</term>
<term>Souris</term>
<term>Grippe A</term>
<term>Réassortiment génétique</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccin</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">H9N2 subtype influenza A viruses have been identified in avian species worldwide and were isolated from humans in 1999, raising concerns about their pandemic potential and prompting the development of candidate vaccines to protect humans against this subtype of influenza A virus. Reassortant H1N1 and H3N2 human influenza A viruses with the internal genes of the influenza A/Ann Arbor/6/60 (H2N2) (AA) cold-adapted (ca) virus have proven to be attenuated and safe as live virus vaccines in humans. Using classical genetic reassortment, we generated a reassortant virus (G9/AA ca) that contains the hemagglutinin and neuraminidase genes from influenza A/chicken/Hong Kong/G9/97 (H9N2) (G9) and six internal gene segments from the AA ca virus. When administered intranasally, the reassortant virus was immunogenic and protected mice from subsequent challenge with wild-type H9N2 viruses, although it was restricted in replication in the respiratory tract of mice. The G9/AA ca virus bears properties that are desirable in a vaccine for humans and is available for clinical evaluation and use, should the need arise.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0264-410X</s0>
</fA01>
<fA02 i1="01"><s0>VACCDE</s0>
</fA02>
<fA03 i2="1"><s0>Vaccine</s0>
</fA03>
<fA05><s2>21</s2>
</fA05>
<fA06><s2>27-30</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>CHEN (H.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MATSUOKA (Y.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>SWAYNE (David)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>CHEN (Q.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>COX (N. J.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>MURPHY (B. R.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>SUBBARAO (K.)</s1>
</fA11>
<fA14 i1="01"><s1>Influenza Branch, CDC</s1>
<s2>Atlanta, GA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Southeast Poultry Research Laboratory, ARS, USDA</s1>
<s2>Athens, GA</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Laboratory of Infectious Diseases, NIAID, NIH, Building 50, Room 6132, MSC 8007, 50 South Drive</s1>
<s2>Bethesda, MD 20892-8007</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA20><s1>4430-4436</s1>
</fA20>
<fA21><s1>2003</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20289</s2>
<s5>354000114965520420</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2004 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>29 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>04-0415778</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Vaccine</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>H9N2 subtype influenza A viruses have been identified in avian species worldwide and were isolated from humans in 1999, raising concerns about their pandemic potential and prompting the development of candidate vaccines to protect humans against this subtype of influenza A virus. Reassortant H1N1 and H3N2 human influenza A viruses with the internal genes of the influenza A/Ann Arbor/6/60 (H2N2) (AA) cold-adapted (ca) virus have proven to be attenuated and safe as live virus vaccines in humans. Using classical genetic reassortment, we generated a reassortant virus (G9/AA ca) that contains the hemagglutinin and neuraminidase genes from influenza A/chicken/Hong Kong/G9/97 (H9N2) (G9) and six internal gene segments from the AA ca virus. When administered intranasally, the reassortant virus was immunogenic and protected mice from subsequent challenge with wild-type H9N2 viruses, although it was restricted in replication in the respiratory tract of mice. The G9/AA ca virus bears properties that are desirable in a vaccine for humans and is available for clinical evaluation and use, should the need arise.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05C07</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Virus grippal A</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Influenza A virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Influenza A virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Influenzavirus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Influenzavirus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Influenzavirus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Souche atténuée</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Attenuated strain</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Cepa atenuada</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Vaccin</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Vaccine</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Vacuna</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Immunogénicité</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Immunogenicity</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Inmunogenicidad</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Immunoprotection</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Immunoprotection</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Inmunoprotección</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Souris</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Mouse</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Ratón</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Grippe A</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Influenza A</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Gripe A</s0>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Réassortiment génétique</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Genetic reassortment</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Influenzavirus A</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Influenzavirus A</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Influenzavirus A</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Virose</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Viral disease</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Virosis</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Infection</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Infection</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Infección</s0>
<s2>NM</s2>
</fC07>
<fN21><s1>236</s1>
</fN21>
<fN44 i1="01"><s1>PSI</s1>
</fN44>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000019 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000019 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    H2N2V1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:04-0415778
   |texte=   Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 14 19:59:40 2020. Site generation: Thu Mar 25 15:38:26 2021

	Serveur d'exploration H2N2
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration H2N2

Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate

Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri